Resonance Health Ltd (ASX: RHT) ('Resonance Health' or 'Company') advises that Mr. Ajay Nair has been appointed to the new role of General Manager - Global Sales & Marketing.

Mr. Nair has over 20 years of sales and marketing experience in the healthcare industry including most recently as Vice President of Sales & Marketing for US med-device company WillowWood. His career started at Ethicon Inc, a subsidiary of Johnson & Johnson, and he went on to hold marketing roles at Eli Lilly and Medtronic. He has held sales leadership and general management roles with Ossur and Leica Biosystems.

Ajay will be responsible for developing and executing Resonance Health's global sales and marketing strategy, leading a global sales team to grow the Company's core business of image analysis services. He will also be responsible for the branding, launch and marketing of new devices including the Company's pipeline of AI solutions. A recruitment drive has commenced for sales personnel in the USA and for product branding and marketing personnel at the Company's head office.

Speaking on Ajay's appointment, Mitchell Wells, Managing Director of Resonance Health said: 'We've started the process of scaling the Company for growth and we're excited to welcome Ajay to Resonance Health. He has vast international experience in medical sales and marketing and has worked throughout South-East Asia, China, and the United States, all core target growth areas for Resonance Health. Over the coming months we will be recruiting a global sales team and increasing our human resources as we continue to transition from development to commercialisation and sales.'

Commenting on his appointment, Ajay Nair said: 'I'm tremendously excited for the opportunity to join such an amazing company at such a crucial time. I am inspired by the Company's mission and its exciting pipeline of best-in-class medical diagnostic products and services. Additionally, Resonance Health's current vantage point of being 'launch ready' with several AI based and critically needed products with an eye towards global commercialisation perfectly fits the experience I bring.'

The Company will provide further updates on key personnel appointments as they are made.

Attachments

  • Original document
  • Permalink

Disclaimer

Resonance Health Limited published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2021 23:32:03 UTC.